24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD, and comparison with formoterol

V. Ninane, E. Derom, J. B. Martinot, M. Higgins, R. Firth, R. Owen, F. Dong (Bruxelles, Gent, Namur, Belgium; West Sussex, United Kingdom; New Jersey, United States Of America)

Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD
Session: Pathogenesis and treatment of asthma and COPD
Session type: Thematic Poster Session
Number: 3609
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
V. Ninane, E. Derom, J. B. Martinot, M. Higgins, R. Firth, R. Owen, F. Dong (Bruxelles, Gent, Namur, Belgium; West Sussex, United Kingdom; New Jersey, United States Of America). 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD, and comparison with formoterol. Eur Respir J 2008; 32: Suppl. 52, 3609

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma, and comparison with formoterol
Source: Annual Congress 2008 - New treatments for asthma
Year: 2008

Efficacy and safety of therapeutic and supratherapeutic doses of indacaterol compared to salmeterol and salbutamol, in mild-to-moderate asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 207s
Year: 2006

Bronchodilator therapy with indacaterol once-daily in COPD: a 52-week comparison with formoterol
Source: Annual Congress 2009 - Next generation bronchodilators
Year: 2009


Qva149, a novel combination of indacaterol and glycopyrronium, demonstrates superior bronchodilation compared with indacaterol or placebo in patients with COPD
Source: Annual Congress 2009 - Next generation bronchodilators
Year: 2009


Superior spirometric efficacy of single dose formoterol compared to single dose salmeterol during the first hour post-dose in moderate and severe COPD patients
Source: Eur Respir J 2001; 18: Suppl. 33, 57s
Year: 2001

NVA237, a once-daily inhaled anticholinergic, provides 24-hour bronchodilator efficacy in patients with moderate-to-severe COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 527s
Year: 2006

Cardiovascular safety of qva149, a novel combination of indacaterol and glycopyrronium, compared with indacaterol and placebo in patients with COPD
Source: Annual Congress 2009 - New bronchodilators
Year: 2009

Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison
Source: Eur Respir J 2011; 37: 273
Year: 2011



Indacaterol once-daily provides effective 24-h bronchodilation in COPD patients: a 26-week evaluation vs placebo and tiotropium
Source: Annual Congress 2009 - New bronchodilators
Year: 2009

Comparison of a combination of tiotropium and formoterol to salmeterol and fluticasone in moderate COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 14s
Year: 2005

Comparison of spirometric efficacy of fluticasone/salmeterol plus tiotropium and tiotropium alone in moderate COPD
Source: Annual Congress 2009 - New bronchodilators
Year: 2009


A pilot study comparing tiotropium to salmeterol plus fluticasone in moderate COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 124s
Year: 2005

Effect of a single dose of formoterol and tiotropium in exercise tolerance in COPD patients: preliminary data
Source: Eur Respir J 2003; 22: Suppl. 45, 405s
Year: 2003

Cardiac safety of indacaterol, a novel once-daily bronchodilator, in COPD
Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD
Year: 2008

Efficacy of nebulized arformoterol, a long-acting β2-adrenergic bronchodilator, in patients with COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 215s
Year: 2006

The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 212s
Year: 2006

Safety and tolerability of high-dose formoterol via aerolizer and salbutamol via MDI in patients with mild-to-moderate COPD
Source: Eur Respir J 2003; 22: Suppl. 45, 285s
Year: 2003

Cost-effectiveness of budesonide and formoterol in a single inhaler compared to fluticasone in the treatment of asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 157s
Year: 2001

Spirometric outcomes of COPD patients with tiotropium compared with salmeterol according to previous maintenance long-acting beta-agonist use
Source: Eur Respir J 2004; 24: Suppl. 48, 289s
Year: 2004

Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD
Source: Eur Respir J 2011; 38: 797-803
Year: 2011